Review of cost-effectiveness analysis of medical treatment for myocardial infarction

International Journal of Preventive Medicine

Volumn 2, Issue 2, 2011, Pages 64-72

  Liu, Yanmei ^a   Dalal, Koustuv ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Cost effectiveness analysis; Heart; Medicine

Indexed keywords

ALTEPLASE; ANISTREPLASE; ENOXAPARIN; HEPARIN; LISINOPRIL; PLACEBO; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADJUVANT THERAPY; ANTERIOR MYOCARDIAL INFARCTION; BLOOD CLOT LYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG USE; HEART INFARCTION; HOME CARE; HUMAN; LIFE EXPECTANCY; OUTCOME ASSESSMENT; PHARMACOEPIDEMIOLOGY; QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK REDUCTION; SENSITIVITY ANALYSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURVIVAL TIME;

EID: 79952715867     PISSN: 20087802     EISSN: 20088213     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28(13): 1598-660.
2. White HD. Evolution of the definition of myocardial infarction: what are the implications of a new universal definition? Heart 2008; 94(6): 679-84.
3. ACC/AHA Guidelines for the Management of Patients with Acute Myocardial Infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Journal Am Coll Cardiol 1999; 34: 890-911.
4. A prospective trial of intravenous streptokinase in acute myocardial infarction (I. S. A. M.). Mortality, morbidity, and infarct size at 21 days. The I. S. A. M. Study Group. N Engl J Med 1986; 314(23): 1465-71.
5. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. AIMS Trial Study Group. Lancet 1988; 1(8585): 545-9.
6. Feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners: Grampian region early anistreplase trial. GREAT Group. BMJ 1992; 305(6853): 548-53.
7. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. Lancet 1992; 339(8796): 753-70.
8. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994; 343(8906): 1115-22.
9. Antman EM, Morrow DA, McCabe CH, Jiang F, White HD, Fox KA, et al. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25). Am Heart J 2005; 149(2): 217-26.
10. Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for STelevation myocardial infarction. N Engl J Med 2006; 354(14): 1477-88.
11. Smith SC, Jr., Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)--executive summary. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol 2001; 37(8): 2215-39.
12. Detsky AS, Naglie IG. A clinician's guide to costeffectiveness analysis. Ann Intern Med 1990; 113(2): 147-54.
13. Eddy DM. Clinical decision making: from theory to practice. Cost-effectiveness analysis. A conversation with my father. JAMA 1992; 267(12): 1669-75.
14. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press, 2005.
15. Vermeer F, Simoons ML, de Zwaan C, van Es GA, Verheugt FW, van der LA, et al. Cost benefit analysis of early thrombolytic treatment with intracoronary streptokinase. Twelve month follow up report of the randomised multicentre trial conducted by the Interuniversity Cardiology Institute of The Netherlands. Br Heart J 1988; 59(5): 527-34.
16. Levin LA, Jonsson B. Cost-effectiveness of thrombolysis--a randomized study of intravenous rt-PA in suspected myocardial infarction. Eur Heart J 1992; 13(1):2-8.
17. Machecourt J, Dumoulin J, Calop J, Foroni L, Terisse MP, Henon T, et al. Cost effectiveness of thrombolytic treatment for myocardial infarction: comparison of anistreplase, alteplase and streptokinase in 270 patients treated within 4 hours. Eur Heart J 1993; 14(1):75-83.
18. Rawles JM. Myocardial salvage with early anistreplase treatment. Clin Cardiol 1997; 20(11 Suppl 3): III6-10.
19. Franzosi MG, Maggioni AP, Santoro E, Tognoni G, Cavalieri E. Cost-effectiveness analysis of early lisinopril use in patients with acute myocardial infarction. Results from GISSI-3 trial. Pharmacoeconomics 1998; 13(3): 337-46.
20. Lorenzoni R, Pagano D, Mazzotta G, Rosen SD, Fattore G, De Caterina R, et al. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups. Eur Heart J 1998; 19(10): 1518-24.
21. Marcoff L, Zhang Z, Zhang W, Ewen E, Jurkovitz C, Leguet P, et al. Cost effectiveness of enoxaparin in acute ST-segment elevation myocardial infarction: the ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction 25) study. J Am Coll Cardiol 2009; 54(14): 1271-9.
22. Welsh RC, Sauriol L, Zhang Z, Kolm P, Weintraub WS, Theroux P. Cost-effectiveness of enoxaparin compared with unfractionated heparin in ST elevation myocardial infarction patients undergoing pharmacological reperfusion: a Canadian analysis of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment - Thrombolysis in Myocardial Infarction (ExTRACT-TIMI) 25 trial. Can J Cardiol 2009; 25(12): e399-405.
23. Launois R, Launois B. [Cost efficacy analysis of thrombolytic strategies]. Arch Mal Coeur Vaiss 1989; 82 Spec No 3: 55-62.
24. Kaul P, Armstrong PW, Cowper PA, Eisenstein EL, Granger CB, Van de WF, et al. Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction. Am Heart J 2005; 149(4): 637-44.
25. Nutescu EA, Steinmetz PK. Economic evaluation of the use of enoxaparin in non-ST-elevation acute coronary syndrome. Expert Opin Pharmacother 2008; 9(1): 95-105.
26. Garas S, Zafari AM. Myocardial Infarction. eMedicine Cardiology 2010.
27. Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for STelevation myocardial infarction. N Engl J Med 2006; 354(14): 1477-88.
28. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993; 329(10): 673-82.